Although BCL-2 inhibitors have been widely studied for their groundbreaking effects in the treatment of hematological neoplasms [46], little is known about targeting BCL-2 for regulating chemokines during the antitumor immune response. The gene discussed is BCL2; the disease is hematopoietic and lymphoid system neoplasm.